Get in touch
Close

Contacts

Sarvodaya Hospital,
Sector 8,
Faridabad, Haryana, India

+ (91) 9355258181

info@theranos.care

Get in touch
Get in touch

Ac-PRRT Therapy for Neuroendocrine Tumors

Summary in a Minute

Ac-225 PRRT (Actinium-225 Peptide Receptor Radionuclide Therapy in India) is a targeted alpha radiation therapy (TAT) designed to treat advanced cancers, especially neuroendocrine tumors (NETs) in India. This therapy uses Actinium-225, a radioactive isotope, attached to a peptide that binds specifically to receptors overexpressed on cancer cells. Once bound, Ac-225 delivers highly effective, localized radiation to destroy tumors while minimizing damage to surrounding healthy tissues. Ac-225 PRRT offers a promising treatment option for patients with advanced or metastatic NETs, improving survival rates and quality of life.

Overview

Ac-225 PRRT (Actinium-225 Peptide Receptor Radionuclide Therapy in India) is a targeted alpha
radiation therapy (TAT) for advanced cancers.

Mechanism of Action

1. Ac-225 is attached to a peptide that binds to somatostatin receptors.
2. The complex targets and binds to cancer cells.
3. Alpha radiation emitted by Ac-225 kills cancer cells.

Indications

1. Advanced neuroendocrine tumors (NETs).
2. Gastroenteropancreatic NETs (GEP-NETs).
3. Somatostatin receptor-positive tumors.
4. Prostate cancer.

Contra-Indications

1. Pregnancy or breastfeeding.
2. Severe kidney impairment.
3. Known hypersensitivity to Ac-225 or somatostatin analogs.

Dosage and Administration

1. Typical dose: 1-2 MBq/kg.
2. Administration: Intravenous injection, usually every 6-8 weeks.
3. Number of cycles: Varies (typically 4-6).

Efficacy

1. Improved progression-free survival: Actinium-225 PRRT therapy in Delhi NCR India helps delay disease progression in advanced cancers.
2. Reduced tumor burden: Targeted radiation shrinks tumors, lowering overall cancer load effectively.
3. Enhanced quality of life: Patients experience reduced symptoms, less pain, and better functionality.

Side Effects

1. Dry Mouth
2. Fatigue
3. Nausea and vomiting
4. Bone marrow suppression
5. Kidney damage (Rare)

Radiation Safety

1. Standard radiation safety protocols.
2. Patient isolation (24-48 hours).

Comparison with Lutetium-PRRT

1. Similar targeting mechanism (somatostatin receptors).
2. Different radioactive isotopes (Ac-225 vs. Lu-177).
3. Alpha particles (Ac-225) offer improved tumor killing thereby faster tumor control and
alleviation of symptoms.

Clinical Trials

1. Phase 1/2 trial (NCT03724747).
2. Phase 2 trial (NCT04150318).

FAQs about Actinium PRRT Therapy

Ac-225 PRRT is a targeted alpha radiation therapy used for treating advanced cancers, particularly neuroendocrine tumors (NETs).

Actinium-225 binds to tumor cells, delivering alpha radiation directly to cancer, destroying cells with minimal side effects.

Yes, it’s generally safe, though potential side effects like fatigue, nausea, or bone marrow suppression may occur.

Treatment typically involves an injection of Ac-225 and takes about 1-2 hours, including preparation and imaging.

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

Contact Information

Contact for appointments for Scans and Therapies.

Phone

+91-9650057298
+91-9355258181

Email
info@theranos.care
Address
Sarvodaya Hospital, 
Sector 8, Faridabad, Haryana, India
Facebook-f X-twitter Linkedin-in Youtube Whatsapp Google

Get in Touch

Define a Clinic or Appointment related query and send to us.